NCT01038063

Brief Summary

A community-based, open-label, cluster-randomised longitudinal study in which children are randomized according to village health worker catchment areas comparing the safety and effectiveness of repeated treatments with artemether-lumefantrine (AL) over a 3-year period in children 4-48 months to that of repeated treatment with dihydroartemisinin-piperaquine (DHA-PPQ).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,200

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Oct 2010

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 21, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 23, 2009

Completed
9 months until next milestone

Study Start

First participant enrolled

October 1, 2010

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2013

Completed
Last Updated

December 9, 2010

Status Verified

December 1, 2010

Enrollment Period

2.9 years

First QC Date

December 21, 2009

Last Update Submit

December 8, 2010

Conditions

Outcome Measures

Primary Outcomes (1)

  • Prevalence of ototoxicity at 18 months and 36 months of enrolment.

    At 18 mo and 36 month of follow up

Secondary Outcomes (1)

  • Incidence of clinical malaria during 18 months and 36 months of follow-up

    18 and 36 months of follow up

Study Arms (2)

Artemether-lumefantrine

EXPERIMENTAL

Children in this study arm will be treated with artemether-lumefantrine during a three year follow-up period each time a child develops uncomplicated malaria.

Drug: Artemether-lumefantrine combination

Dihydroartemisinin-piperaquine

ACTIVE COMPARATOR

Children in this study arm will be treated with dihydroartemisinin-piperaquine during a three year follow-up period each time a child develops uncomplicated malaria.

Drug: Artemether-lumefantrine combination

Interventions

Artemether-lumefantrineDihydroartemisinin-piperaquine

Eligibility Criteria

Age4 Months - 48 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Aged between 4 months and 11 months at the time of randomization
  • Bodyweight ≥ 5 kg at the time of randomization
  • Provision of informed consent by parent or guardian
  • Intention to stay in the study area for the time of the study

You may not qualify if:

  • Ongoing participation into another clinical study involving ongoing or scheduled treatment with medicinal products
  • Intent to reside outside of catchment area during the course of the study
  • Known hypersensitivity to the study drug randomized to
  • Known pre-existing hearing problem or neurological impairment
  • Known need at the time of randomization for concomitant prohibited medication
  • Suspected non-compliance with the follow-up schedule

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Malawi-Liverpool-Wellcome Trust Research Programme, College of Medicine

Blantyre, 30096, Malawi

RECRUITING

Related Publications (1)

  • Roca-Feltrer A, Lalloo DG, Phiri K, Terlouw DJ. Rolling Malaria Indicator Surveys (rMIS): a potential district-level malaria monitoring and evaluation (M&E) tool for program managers. Am J Trop Med Hyg. 2012 Jan;86(1):96-8. doi: 10.4269/ajtmh.2012.11-0397.

MeSH Terms

Conditions

Malaria

Interventions

Artemether, Lumefantrine Drug Combination

Condition Hierarchy (Ancestors)

Protozoan InfectionsParasitic DiseasesInfectionsMosquito-Borne DiseasesVector Borne Diseases

Intervention Hierarchy (Ancestors)

ArtemetherArtemisininsReactive Oxygen SpeciesFree RadicalsInorganic ChemicalsOrganic ChemicalsLumefantrineFluorenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsSesquiterpenesTerpenesPolycyclic CompoundsDrug CombinationsPharmaceutical Preparations

Study Officials

  • David Lalloo, MD

    Liverpool School of Tropical Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 21, 2009

First Posted

December 23, 2009

Study Start

October 1, 2010

Primary Completion

September 1, 2013

Study Completion

September 1, 2013

Last Updated

December 9, 2010

Record last verified: 2010-12

Locations